KDOQI对KDIGO 2025 ADPKD指南的美国实践解读
KDOQI工作组审查了KDIGO 2025常染色体显性多囊肾病(ADPKD)临床实践指南,并结合美国临床实践提供实施视角。工作组总体认同KDIGO关于诊断、肾脏表现、CKD管理、延缓进展治疗及肾外表现管理的推荐,并讨论了实施障碍与机会。
要点
- KDOQI总体认同KDIGO 2025 ADPKD指南的诊断与管理推荐
- 工作组支持ADPKD命名变更的循证依据
- 实施指南需关注美国临床实践中的障碍与机会
核心结论
- KDOQI工作组总体认同KDIGO 2025 ADPKD指南中关于诊断、肾脏表现、CKD管理、延缓进展治疗及肾外表现管理的推荐和实践要点。
研究设计与样本
- KDOQI召集工作组审查KDIGO 2025 ADPKD临床实践指南,并提供美国临床实践背景下的实施视角。
主要发现
- 工作组认同KDIGO关于ADPKD诊断、肾脏表现、CKD管理与进展、延缓进展治疗及肾外表现管理的多项推荐。
- 工作组注意到支持ADPKD命名变更的证据基础不断增长。
- 工作组评估并讨论了实施KDIGO 2025指南推荐的障碍与潜在机会。
临床怎么用
- 可参考KDOQI解读在美国临床实践中实施KDIGO 2025 ADPKD指南推荐。
- 实施时需考虑工作组识别的障碍与机会,并关注支持特定推荐的前瞻性高质量证据。
局限性
- 该文件为KDOQI对KDIGO指南的评论,并非原始研究。
- 部分推荐仍需前瞻性高质量证据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2025 KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD). The KDOQI work group reviewed the KDIGO guideline statements and practice points and provided perspective for implementation within the context of clinical practice in the United States. In general, the KDOQI work group concurs with several recommendations and practice points proposed by the KDIGO guidelines regarding the diagnosis, kidney manifestations of ADPKD, chronic kidney disease management and progression, and therapies to delay the progression of disease, along with management of extrarenal manifestations. The KDOQI work group acknowledges the growing evidence base to support a change in the nomenclature for ADPKD. In this commentary, the work group has also assessed and discussed various barriers and potential opportunities for implementing the recommendations put forth in the 2025 KDIGO guidelines while the scientific community continues to focus on prospective high-quality evidence to support specific recommendations for this systemic condition.
引用
- Dahl NK, August P, Besse W, et al. KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Am J Kidney Dis. 2026. PMID: 41864657. doi:10.1053/j.ajkd.2025.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。